{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:27:04Z","timestamp":1778113624865,"version":"3.51.4"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cascade testing (CT) is an effective instrument for identifying an index patient\u2019s relatives at high risk of a heritable condition enabling informed decision-making on preventive interventions and reproductive choice. However, CT remains underutilised and faces barriers. Discussions are ongoing on how to optimise informing family members and testing uptake in a responsible manner. The European Society of Human Genetics (ESHG) contributes to this debate and provides recommendations based on an ethical analysis of when CT is justified, or may be less compelling, considering proportionality and the judicious use of finite resources. ESHG underscores the strong consensus regarding the \u2018moral architecture\u2019 of CT in cases of a high risk of serious, avoidable harm. In such cases, a more active approach towards CT is suggested, including a more directive approach in counselling, more active support for the proband, direct contacting, and balancing confidentiality when this is necessary to avoid a high risk of serious harm, taking account of national regulations and jurisdictions. In contrast, more caution is advised in more complex cases where the balance of benefits and harms of CT is less clear, such as when penetrance is low, and actionability or medical treatment is limited. This more cautious approach does not call for directivity, direct contact or the relaxing of medical confidentiality. The focus, then, shifts to cascade counselling, rather than cascade testing. In some cases, CT may not be proportional or appropriate given the balance between benefits and harms, also in view of available resources.<\/jats:p>","DOI":"10.1038\/s41431-025-01945-3","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T04:14:18Z","timestamp":1765685658000},"page":"171-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cascade counselling and testing. Recommendations of the European Society of Human Genetics"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4902","authenticated-orcid":false,"given":"Guido","family":"de Wert","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-2320","authenticated-orcid":false,"given":"Carla G.","family":"van El","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-9286","authenticated-orcid":false,"given":"Angus","family":"Clarke","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Cordier","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-4768","authenticated-orcid":false,"given":"Florence","family":"Fellmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-8351","authenticated-orcid":false,"given":"Maurizio","family":"Genuardi","sequence":"additional","affiliation":[]},{"given":"Sabine","family":"Hentze","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-499X","authenticated-orcid":false,"given":"H\u00fclya","family":"Kayserili","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-5280","authenticated-orcid":false,"given":"Milan","family":"Macek","sequence":"additional","affiliation":[]},{"given":"Rhona","family":"MacLeod","sequence":"additional","affiliation":[]},{"given":"B\u00e9la","family":"Melegh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8766-7646","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Emmanuelle","family":"Rial-Sebbag","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-3126","authenticated-orcid":false,"given":"Vigd\u00eds","family":"Stef\u00e1nsd\u00f3ttir","sequence":"additional","affiliation":[]},{"given":"Lisbeth","family":"Tranebj\u00e6rg","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-6542","authenticated-orcid":false,"given":"Fiona","family":"Ulph","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-0052","authenticated-orcid":false,"given":"Francesca","family":"Forzano","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"1945_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ajmg.1320260208","volume":"26","author":"AT Lamport","year":"1987","unstructured":"Lamport AT. Presymptomatic testing for Huntington's chorea: ethical and legal issues. Am J Med Genet. 1987;26:307\u201314.","journal-title":"Am J Med Genet"},{"key":"1945_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41431-018-0103-9","volume":"26","author":"D d\u2019Audiffret Van Haecke","year":"2018","unstructured":"d\u2019Audiffret Van Haecke D, de Montgolfier S. Genetic diseases and information to relatives: practical and ethical issues for professionals after introduction of a legal framework in France. Eur J Hum Genet. 2018;26:786\u201395.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-020-0451-1","volume":"21","author":"N Meggiolaro","year":"2020","unstructured":"Meggiolaro N, Barlow-Stewart K, Dunlop K, Newson AJ, Fleming J. Disclosure to genetic relatives without consent\u2014Australian genetic professionals\u2019 awareness of the health privacy law. BMC Med Ethics. 2020;21:13.","journal-title":"BMC Med Ethics"},{"key":"1945_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41436-021-01248-0","volume":"23","author":"A Phillips","year":"2021","unstructured":"Phillips A, Borry P, Van Hoyweghen I, Vears DF. Disclosure of genetic information to family members: a systematic review of normative documents. Genet Med. 2021;23:2038\u201346.","journal-title":"Genet Med"},{"key":"1945_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10689-023-00356-x","volume":"23","author":"LA Grutters","year":"2024","unstructured":"Grutters LA, Christiaans I. Cascade genetic counseling and testing in hereditary syndromes: inherited cardiovascular disease as a model: a narrative review. Fam Cancer. 2024;23:155\u201364.","journal-title":"Fam Cancer"},{"key":"1945_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10689-018-0089-z","volume":"18","author":"FH Menko","year":"2019","unstructured":"Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, et al. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice. Fam Cancer. 2019;18:127\u201335.","journal-title":"Fam Cancer"},{"key":"1945_CR7","doi-asserted-by":"crossref","unstructured":"Menko FH, van der Velden SL, Griffioen DN, Ait Moha D, Jeanson KN, Hogervorst FBL, et al. Does a proactive procedure lead to a higher uptake of predictive testing in families with a pathogenic BRCA1\/BRCA2 variant? A family cancer clinic evaluation. J Genet Couns. 2023;33:615\u201322.","DOI":"10.1002\/jgc4.1767"},{"key":"1945_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pecinn.2023.100138","volume":"2","author":"MD Ahsan","year":"2023","unstructured":"Ahsan MD, Levi SR, Webster EM, Bergeron H, Lin J, Narayan P, et al. Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis. PEC Innov. 2023;2:100138.","journal-title":"PEC Innov"},{"key":"1945_CR9","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41431-020-00725-5","volume":"28","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC. Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet. 2020;28:1631\u201344.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.ejhg.5201360","volume":"13","author":"AJ Newson","year":"2005","unstructured":"Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted?. European J Hum Genet. 2005;13:401\u20138.","journal-title":"European J Hum Genet"},{"key":"1945_CR11","doi-asserted-by":"crossref","unstructured":"van El CG, Baccolini V, Piko P, Cornel MC. Stakeholder views on active cascade screening for familial hypercholesterolemia. Healthcare. 2018;6.","DOI":"10.3390\/healthcare6030108"},{"key":"1945_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1377\/hlthaff.2017.1630","volume":"37","author":"MC Roberts","year":"2018","unstructured":"Roberts MC, Dotson WD, DeVore CS, Bednar EM, Bowen DJ, Ganiats TG, et al. Delivery of cascade screening for hereditary conditions: a scoping review of the literature. Health Aff. 2018;37:801\u20138.","journal-title":"Health Aff"},{"key":"1945_CR13","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.22.00303","volume":"40","author":"MK Frey","year":"2022","unstructured":"Frey MK, Ahsan MD, Bergeron H, Lin J, Li X, Fowlkes RK, et al. Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis. J Clin Oncol. 2022;40:4129\u201343.","journal-title":"J Clin Oncol"},{"key":"1945_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/jgc4.1206","volume":"29","author":"LM van den Heuvel","year":"2020","unstructured":"van den Heuvel LM, Stemkens D, van Zelst-Stams WAG, Willeboordse F, Christiaans I. How to inform at-risk relatives? Attitudes of 1379 Dutch patients, relatives, and members of the general population. J Genet Couns. 2020;29:786\u201399.","journal-title":"J Genet Couns"},{"key":"1945_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/jgc4.1143","volume":"28","author":"LM van den Heuvel","year":"2019","unstructured":"van den Heuvel LM, Smets EMA, van Tintelen JP, Christiaans I. How to inform relatives at risk of hereditary diseases? A mixed-methods systematic review on patient attitudes. J Genet Couns. 2019;28:1042\u201358.","journal-title":"J Genet Couns"},{"key":"1945_CR16","doi-asserted-by":"crossref","unstructured":"Lindberg LJ, Wadt KAW, Therkildsen C, Petersen HV. National experiences from 30 years of provider-mediated cascade testing in Lynch syndrome families\u2014The Danish model. Cancers. 2024;16.","DOI":"10.3390\/cancers16081577"},{"key":"1945_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/medethics-2018-105229","volume":"45","author":"ES Dove","year":"2019","unstructured":"Dove ES, Chico V, Fay M, Laurie G, Lucassen AM, Postan E. Familial genetic risks: how can we better navigate patient confidentiality and appropriate risk disclosure to relatives?. J Med Ethics. 2019;45:504\u20137.","journal-title":"J Med Ethics"},{"key":"1945_CR18","doi-asserted-by":"crossref","unstructured":"Hawranek C, Hajdarevic S, Ros\u00e9n A. A focus group study of perceptions of genetic risk disclosure in members of the public in Sweden: \u201cI\u2019ll phone the five closest ones, but what happens to the other ten?\u201d. J Pers Med. 2021;11:1191.","DOI":"10.3390\/jpm11111191"},{"key":"1945_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41431-021-00993-9","volume":"30","author":"LM van den Heuvel","year":"2022","unstructured":"van den Heuvel LM, Hoedemaekers YM, Baas AF, Baars MJH, van Tintelen JP, Smets EMA, et al. A tailored approach to informing relatives at risk of inherited cardiac conditions: results of a randomised controlled trial. Eur J Hum Genet. 2022;30:203\u201310.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(19)32941-1","volume":"394","author":"A Middleton","year":"2019","unstructured":"Middleton A, Milne R, Robarts L, Roberts J, Patch C. Should doctors have a legal duty to warn relatives of their genetic risks?. Lancet. 2019;394:2133\u20135.","journal-title":"Lancet"},{"key":"1945_CR21","unstructured":"VKGN. Richtlijn informeren van familieleden bij erfelijke aandoeningen. In: Richtlijnendatabase. Federatie Medisch Specialisten. 2019. https:\/\/richtlijnendatabase.nl\/richtlijn\/informeren_van_familieleden_bij_erfelijke_aandoeningen\/startpagina_-_informeren_van_familieleden_bij_erfelijke_aandoeningen.html. Accessed 10 Oct 2025."},{"key":"1945_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41431-021-01016-3","volume":"30","author":"A Phillips","year":"2022","unstructured":"Phillips A, Bronselaer T, Borry P, Van Hoyweghen I, Vears DF, Pasquier L, et al. Informing relatives of their genetic risk: an examination of the Belgian legal context. Eur J Hum Genet. 2022;30:766\u201371.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","volume":"29","author":"G de Wert","year":"2021","unstructured":"de Wert G, Dondorp W, Clarke A, Dequeker EMC, Cordier C, Deans Z, et al. Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2021;29:365\u201377.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR24","unstructured":"Centers for Disease Control and Preventon. Tier 1 Genomics Applications and their Importance to Public Health. Archived 2024. https:\/\/archive.cdc.gov\/www_cdc_gov\/genomics\/implementation\/toolkit\/tier1.htm. Accessed 10 Oct 2025."},{"key":"1945_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102159","volume":"64","author":"L Jackson","year":"2023","unstructured":"Jackson L, Weedon MN, Green HD, Mallabar-Rimmer B, Harrison JW, Wood AR, et al. Influence of family history on penetrance of hereditary cancers in a population setting. EClinicalMedicine. 2023;64:102159.","journal-title":"EClinicalMedicine"},{"key":"1945_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev-genom-083118-015253","volume":"21","author":"R Manchanda","year":"2020","unstructured":"Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E. Population screening for inherited predisposition to breast and ovarian cancer. Annu Rev Genom Hum Genet. 2020;21:373\u2013412.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"1945_CR27","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.19.02010","volume":"38","author":"K Offit","year":"2020","unstructured":"Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, et al. Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening. J Clin Oncol. 2020;38:1398\u2013408.","journal-title":"J Clin Oncol"},{"key":"1945_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/M22-0846","volume":"176","author":"GF Guzauskas","year":"2023","unstructured":"Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, et al. Population genomic screening for three common hereditary conditions : a cost-effectiveness analysis. Ann Intern Med. 2023;176:585\u201395.","journal-title":"Ann Intern Med"},{"key":"1945_CR29","unstructured":"US NIH National Cancer Institute. Dictionary of Genetics Terms. In: NCI Dictionaries. https:\/\/www.cancer.gov\/publications\/dictionaries\/genetics-dictionary\/def\/cascade-testing. Accessed 10 Oct 2025."},{"key":"1945_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-022-01142-9","volume":"8","author":"PR Blasi","year":"2022","unstructured":"Blasi PR, Scrol A, Anderson ML, Gray MF, Tiffany B, Fullerton SM, et al. Feasibility, acceptability, and limited efficacy of health system-led familial risk notification: protocol for a mixed-methods evaluation. Pilot Feasibility Stud. 2022;8:174.","journal-title":"Pilot Feasibility Stud"},{"key":"1945_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/gim.2013.73","volume":"15","author":"RC Green","year":"2013","unstructured":"Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565\u201374.","journal-title":"Genet Med"},{"key":"1945_CR32","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1038\/sj.ejhg.5201117","volume":"11","author":"B Godard","year":"2003","unstructured":"Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Aym\u00e9 S. Genetic information and testing in insurance and employment: technical, social and ethical issues. European J Hum Genet. 2003;11:S123\u2013S42.","journal-title":"European J Hum Genet"},{"key":"1945_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10689-018-0083-5","volume":"18","author":"HV Petersen","year":"2019","unstructured":"Petersen HV, Frederiksen BL, Lautrup CK, Lindberg LJ, Ladelund S, Nilbert M. Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes. Fam Cancer. 2019;18:43\u201351.","journal-title":"Fam Cancer"},{"key":"1945_CR34","first-page":"1","volume":"19","author":"BE Berkman","year":"2017","unstructured":"Berkman BE. Refuting the right not to know. J Health Care Law Policy. 2017;19:1\u201372.","journal-title":"J Health Care Law Policy"},{"key":"1945_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.ejhg.5201373","volume":"13","author":"G de Wert","year":"2005","unstructured":"de Wert G. Cascade screening: whose information is it anyway? Eur J Hum Genet. 2005;13:397\u20138.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR36","doi-asserted-by":"crossref","unstructured":"Clarke A. Genetic counselling. Practice and principles. London and New York: Routledge; 1994.","DOI":"10.4324\/9780203308950"},{"key":"1945_CR37","unstructured":"Clarke A. Challenges to genetic privacy: the control of personal genetic information. In: Clarke PHA, editor. Genetics, society and clinical practice. Oxford: Bios Scientific Publishers; 1997. p 149\u201364."},{"key":"1945_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/sj.ejhg.5201394","volume":"13","author":"A Clarke","year":"2005","unstructured":"Clarke A, Richards M, Kerzin-Storrar L, Halliday J, Young MA, Simpson SA, et al. Genetic professionals\u2019 reports of nondisclosure of genetic risk information within families. Eur J Hum Genet. 2005;13:556\u201362.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ejhg.2009.25","volume":"17","author":"P Borry","year":"2009","unstructured":"Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K. Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet. 2009;17:711\u20139.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR40","unstructured":"Royal College of Physicians, Royal College of Pathologists and British Society for Genetic Medicine. Genetic testing in childhood. Guidance for clinical practice. Report of the Joint Committee on Genomics in Medicine. 2022. https:\/\/www.rcpath.org\/static\/643b3860-5eee-4dfe-b44c862d7af66640\/Genetic-testing-in-childhood.pdf, Accessed Oct 10 2025."},{"key":"1945_CR41","unstructured":"de Wert G. Met het oog op de toekomst: voortplantingstechnologie, erfelijkheidsonderzoek en ethiek. Amsterdam: Thela Thesis; 1999."},{"key":"1945_CR42","unstructured":"Montgomery J. The rights and interests of children and those with a mental handicap. In: Clarke A, editor. Genetic counseling practice and principles. London\/New York: Routledge; 1994. p. 208\u201322."},{"key":"1945_CR43","unstructured":"Feinberg J. The child\u2019s right to an open future In: Follette WAaHL, editor. Whose child? Children\u2019s rights, parental authority and state power. Totowa, NJ: Rowman and Littlefield; 1980, 1980. p. 124\u201353."},{"key":"1945_CR44","doi-asserted-by":"crossref","unstructured":"Davis D. Genetic dilemmas. Reproductive technology, parental choices, and children\u2019s futures. Oxford: Oxford University Press; 2010.","DOI":"10.1093\/oso\/9780195374384.001.0001"},{"key":"1945_CR45","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425\u201337.","journal-title":"Eur Heart J"},{"key":"1945_CR46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547\u201356.","journal-title":"N Engl J Med"},{"key":"1945_CR47","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/sj.ejhg.5201822","volume":"15","author":"LE Forrest","year":"2007","unstructured":"Forrest LE, Delatycki MB, Skene L, Aitken M. Communicating genetic information in families\u2014a review of guidelines and position papers. Eur J Hum Genet. 2007;15:612\u20138.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR48","doi-asserted-by":"publisher","first-page":"k1409","DOI":"10.1136\/bmj.k1409","volume":"361","author":"A Lucassen","year":"2018","unstructured":"Lucassen A, Gilbar R. Alerting relatives about heritable risks: the limits of confidentiality. BMJ. 2018;361:k1409.","journal-title":"BMJ"},{"key":"1945_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bmj.329.7458.165","volume":"329","author":"M Parker","year":"2004","unstructured":"Parker M, Lucassen AM. Genetic information: a joint account?. BMJ. 2004;329:165\u20137.","journal-title":"BMJ"},{"key":"1945_CR50","unstructured":"World Medical Association. Declaration of Reykjavik\u2014Ethical considerations regarding the use of genetics in health care. 2022. https:\/\/www.wma.net\/policies-post\/wma-statement-on-genetics-and-medicine\/. Accessed 10 Oct 2025."},{"key":"1945_CR51","unstructured":"United Kingdom General Medical Council. Confidentiality: good practice in handling patient information. Professional Standards 2017. https:\/\/www.gmc-uk.org\/professional-standards\/the-professional-standards\/confidentiality. Accessed 10 Oct 2025."},{"key":"1945_CR52","unstructured":"Royal College of Physicians, Royal College of Pathologists and British Society for Genetic Medicine. Consent and confidentiality in genomic medicine: Guidance on the use of genetic and genomic information in the clinic. 3rd edition. Report of the Joint Committee on Genomics in Medicine. 2019. https:\/\/www.rcpath.org\/static\/d3956d4a-319e-47ca-8ece8a122949e701\/Consent-and-confidentiality-in-genomic-medicine-July-2019.pdf. Accessed 10 Oct 2025."},{"key":"1945_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.867226","volume":"13","author":"TJ Schmidlen","year":"2022","unstructured":"Schmidlen TJ, Bristow SL, Hatchell KE, Esplin ED, Nussbaum RL, Haverfield EV. The impact of proband indication for genetic testing on the uptake of cascade testing among relatives. Front Genet. 2022;13:867226.","journal-title":"Front Genet"},{"key":"1945_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09304-y","volume":"23","author":"G Campbell-Salome","year":"2023","unstructured":"Campbell-Salome G, Jones LK, Walters NL, Morgan KM, Brangan A, Ladd IG, et al. Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia. BMC Health Serv Res. 2023;23:340.","journal-title":"BMC Health Serv Res"},{"key":"1945_CR55","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ejhg.2015.174","volume":"24","author":"\u00c1 Mendes","year":"2016","unstructured":"Mendes \u00c1, Paneque M, Sousa L, Clarke A, Sequeiros J. How communication of genetic information within the family is addressed in genetic counselling: a systematic review of research evidence. Eur J Hum Genet. 2016;24:315\u201325.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10897-017-0164-x","volume":"27","author":"S Dheensa","year":"2018","unstructured":"Dheensa S, Lucassen A, Fenwick A. Limitations and pitfalls of using family letters to communicate genetic risk: a qualitative study with patients and healthcare professionals. J Genet Couns. 2018;27:689\u2013701.","journal-title":"J Genet Couns"},{"key":"1945_CR57","first-page":"40","volume":"19","author":"SC O\u2019Neill","year":"2021","unstructured":"O\u2019Neill SC, Hamilton JG, Conley CC, Peshkin BN, Sacca R, McDonnell GA, et al. Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report. Hered Cancer Clin Pr. 2021;19:40.","journal-title":"Hered Cancer Clin Pr"},{"key":"1945_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-020-00864-0","volume":"14","author":"C Jujjavarapu","year":"2021","unstructured":"Jujjavarapu C, Anandasakaran J, Amendola LM, Haas C, Zampino E, Henrikson NB, et al. ShareDNA: a smartphone app to facilitate family communication of genetic results. BMC Med Genom. 2021;14:10.","journal-title":"BMC Med Genom"},{"key":"1945_CR59","doi-asserted-by":"crossref","unstructured":"Phillips A. Digital tools for sharing genetic information with family members. Lancet Oncol. 2020; 21:891\u20132.","DOI":"10.1016\/S1470-2045(20)30106-6"},{"key":"1945_CR60","doi-asserted-by":"crossref","unstructured":"Goodman S, Skirton H, Jackson L, Jones RB. Development of a secure website to facilitate information sharing in families at high risk of bowel cancer\u2014the Familyweb study. Cancers. 2021;13:2404.","DOI":"10.3390\/cancers13102404"},{"key":"1945_CR61","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10897-007-9113-4","volume":"16","author":"PM Veach","year":"2007","unstructured":"Veach PM, Bartels DM, Leroy BS. Coming full circle: a reciprocal-engagement model of genetic counseling practice. J Genet Couns. 2007;16:713\u201328.","journal-title":"J Genet Couns"},{"key":"1945_CR62","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jmg.37.2.135","volume":"37","author":"G Elwyn","year":"2000","unstructured":"Elwyn G, Gray J, Clarke A. Shared decision making and non-directiveness in genetic counselling. J Med Genet. 2000;37:135\u20138.","journal-title":"J Med Genet"},{"key":"1945_CR63","doi-asserted-by":"crossref","unstructured":"Clarke AJ. The evolving concept of nondirectiveness in genetic counselling. In: P. Harper SD, & H. Petermann editor. History of human genetics: Aspects of its development and global perspectives. Cham: Springer International Publishing; 2017. pp. 541\u2013566.","DOI":"10.1007\/978-3-319-51783-4_31"},{"key":"1945_CR64","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41431-024-01605-y","volume":"32","author":"\u00c1 Mendes","year":"2024","unstructured":"Mendes \u00c1, Newson AJ. Liminality between direct and family-mediated contact in the communication of genetic information to at-risk relatives. Eur J Hum Genet. 2024;32:477\u20138.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104800","volume":"66","author":"A Phillips","year":"2023","unstructured":"Phillips A, Dewitte I, Debruyne B, Vears DF, Borry P. Disclosure of genetic risk in the family: a survey of the Flemish general population. Eur J Med Genet. 2023;66:104800.","journal-title":"Eur J Med Genet"},{"key":"1945_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13053-020-00151-0","volume":"18","author":"A Andersson","year":"2020","unstructured":"Andersson A, Hawranek C, \u00d6fverholm A, Ehrencrona H, Grill K, Hajdarevic S, et al. Public support for healthcare-mediated disclosure of hereditary cancer risk information: results from a population-based survey in Sweden. Hered Cancer Clin Pract. 2020;18:18.","journal-title":"Hered Cancer Clin Pract"},{"key":"1945_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10689-015-9854-4","volume":"15","author":"E Sermijn","year":"2016","unstructured":"Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, et al. The impact of an interventional counselling procedure in families with a BRCA1\/2 gene mutation: efficacy and safety. Fam Cancer. 2016;15:155\u201362.","journal-title":"Fam Cancer"},{"key":"1945_CR68","unstructured":"Decree 2013\u2013527 of 20 June 2013 on the conditions for the information of relatives in the context of an examination of genetic characteristics with a medical purpose (In French). Articles R.1131-20-1 to 1131-20-5, French Republic. 2013, updated 2023. https:\/\/www.legifrance.gouv.fr\/loda\/id\/LEGIARTI000027594193\/2013-06-23#LEGIARTI000027594193. Accessed 10 Oct 2025."},{"key":"1945_CR69","doi-asserted-by":"publisher","first-page":"e32568","DOI":"10.2196\/32568","volume":"9","author":"H Bangash","year":"2022","unstructured":"Bangash H, Makkawy A, Gundelach JH, Miller AA, Jacobson KA, Kullo IJ. Web-based tool (FH Family Share) to increase uptake of cascade testing for familial hypercholesterolemia: development and evaluation. JMIR Hum Factors. 2022;9:e32568.","journal-title":"JMIR Hum Factors"},{"key":"1945_CR70","unstructured":"R246 Carrier testing at population risk for partners of known carriers of nationally agreed autosomal recessive disorders. In: National Genomic Test Directory. Testing Criteria for Rare and Inherited Disease. National Health Service England. Version 8.1, 2025. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/08\/rare-and-inherited-disease-eligibility-criteria-V8.1.pdf. Accessed 9 Oct 2025."},{"key":"1945_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13570","volume":"13","author":"J Kai","year":"2009","unstructured":"Kai J, Ulph F, Cullinan T, Qureshi N. Communication of carrier status information following universal newborn screening for sickle cell disorders and cystic fibrosis: qualitative study of experience and practice. Health Technol Assess. 2009;13:1\u201382.","journal-title":"Health Technol Assess"},{"key":"1945_CR72","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(00)04240-9","volume":"357","author":"A Lucassen","year":"2001","unstructured":"Lucassen A, Parker M. Revealing false paternity: some ethical considerations. Lancet. 2001;357:1033\u20135.","journal-title":"Lancet"},{"key":"1945_CR73","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28:1379\u201386.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jmedgenet-2020-106876","volume":"58","author":"H Hanson","year":"2020","unstructured":"Hanson H, Brady AF, Crawford G, Eeles RA, Gibson S, Jorgensen M, et al. UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. 2020;58:135\u20139.","journal-title":"J Med Genet"},{"key":"1945_CR75","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz CP, Achatz MI, Brugi\u00e8res L, Frebourg T, Garber JE, Greer MC, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23:e38\u2013e45.","journal-title":"Clin Cancer Res"},{"key":"1945_CR76","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s10147-021-02011-w","volume":"26","author":"T Kumamoto","year":"2021","unstructured":"Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021;26:2161\u201378.","journal-title":"Int J Clin Oncol"},{"key":"1945_CR77","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1056\/NEJMp1803542","volume":"378","author":"SNC Elmore","year":"2018","unstructured":"Elmore SNC. p53 and Me. N Engl J Med. 2018;378:1962\u20133.","journal-title":"N Engl J Med"},{"key":"1945_CR78","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1158\/1078-0432.CCR-17-0834","volume":"23","author":"H Druker","year":"2017","unstructured":"Druker H, Zelley K, McGee RB, Scollon SR, Kohlmann WK, Schneider KA, et al. Genetic counselor recommendations for cancer predisposition evaluation and surveillance in the pediatric oncology patient. Clin Cancer Res. 2017;23:e91\u2013e7.","journal-title":"Clin Cancer Res"},{"key":"1945_CR79","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/humupd\/dms058","volume":"19","author":"CE de Die-Smulders","year":"2013","unstructured":"de Die-Smulders CE, de Wert GM, Liebaers I, Tibben A, Evers-Kiebooms G. Reproductive options for prospective parents in families with Huntington\u2019s disease: clinical, psychological and ethical reflections. Hum Reprod Update. 2013;19:304\u201315.","journal-title":"Hum Reprod Update"},{"key":"1945_CR80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","volume":"83","author":"R MacLeod","year":"2013","unstructured":"MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A, et al. Recommendations for the predictive genetic test in Huntington\u2019s disease. Clin Genet. 2013;83:221\u201331.","journal-title":"Clin Genet"},{"key":"1945_CR81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1034\/j.1399-0004.2003.00142.x","volume":"64","author":"K Forrest","year":"2003","unstructured":"Forrest K, Simpson SA, Wilson BJ, van Teijlingen ER, McKee L, Haites N, et al. To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet. 2003;64:317\u201326.","journal-title":"Clin Genet"},{"key":"1945_CR82","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2307\/3563159","volume":"20","author":"A Lynch","year":"1990","unstructured":"Lynch A, Czeizel A, Salzano FM, Berg K. The price of silence. Hastings Cent Rep. 1990;20:31.","journal-title":"Hastings Cent Rep"},{"key":"1945_CR83","unstructured":"Kuitert H. Erfelijkheidsvoorlichting als informatieprobleem. Ethisch omgaan met erfelijkheidsaspecten bij zwakzinnigheid. Syllabus. Maastricht (In Dutch): Instituut voor Gezondheidsethiek; 1986."},{"key":"1945_CR84","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.socscimed.2009.02.049","volume":"68","author":"K Forrest Keenan","year":"2009","unstructured":"Forrest Keenan K, van Teijlingen E, McKee L, Miedzybrodzka Z, Simpson SA. How young people find out about their family history of Huntington\u2019s disease. Soc Sci Med. 2009;68:1892\u2013900.","journal-title":"Soc Sci Med"},{"key":"1945_CR85","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/ejhg.2010.258","volume":"19","author":"A Metcalfe","year":"2011","unstructured":"Metcalfe A, Plumridge G, Coad J, Shanks A, Gill P. Parents\u2019 and children\u2019s communication about genetic risk: a qualitative study, learning from families\u2019 experiences. Eur J Hum Genet. 2011;19:640\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105725","volume":"171","author":"A Novati","year":"2022","unstructured":"Novati A, Nguyen HP, Schulze-Hentrich J. Environmental stimulation in Huntington disease patients and animal models. Neurobiol Dis. 2022;171:105725.","journal-title":"Neurobiol Dis"},{"key":"1945_CR87","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/ejhg.2016.36","volume":"24","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, et al. 22 Years of predictive testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s Prediction Consortium. Eur J Hum Genet. 2016;24:1396\u2013402.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR88","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jgc4.1415","volume":"30","author":"\u00c1 Mendes","year":"2021","unstructured":"Mendes \u00c1, Sequeiros J, Clarke AJ. Between responsibility and desire: accounts of reproductive decisions from those at risk for or affected by late-onset neurological diseases. J Genet Couns. 2021;30:1480\u201390.","journal-title":"J Genet Couns"},{"key":"1945_CR89","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.ejhg.5200781","volume":"10","author":"G Evers-Kiebooms","year":"2002","unstructured":"Evers-Kiebooms G, Nys K, Harper P, Zoeteweij M, D\u00fcrr A, Jacopini G, et al. Predictive DNA-testing for Huntington\u2019s disease and reproductive decision making: a European collaborative study. Eur J Hum Genet. 2002;10:167\u201376.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR90","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/ejhg.2016.59","volume":"24","author":"H Bouchghoul","year":"2016","unstructured":"Bouchghoul H, Cl\u00e9ment SF, Vauthier D, Cazeneuve C, Noel S, Dommergues M, et al. Prenatal testing in Huntington's disease: after the test, choices recommence. Eur J Hum Genet. 2016;24:1535\u201340.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR91","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jmg-2022-108477","volume":"60","author":"L Pierron","year":"2023","unstructured":"Pierron L, Tezenas du Montcel S, Heinzmann A, Coarelli G, H\u00e9ron D, Heide S, et al. Reproductive choices and intrafamilial communication in neurogenetic diseases with different self-estimated severities. J Med Genet. 2023;60:346\u201351.","journal-title":"J Med Genet"},{"key":"1945_CR92","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13557858.2011.556245","volume":"16","author":"F Ulph","year":"2011","unstructured":"Ulph F, Cullinan T, Qureshi N, Kai J. Familial influences on antenatal and newborn haemoglobinopathy screening. Ethn Health. 2011;16:361\u201375.","journal-title":"Ethn Health"},{"key":"1945_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajmg.10212","volume":"108","author":"DC Wertz","year":"2002","unstructured":"Wertz DC, Knoppers BM. Serious genetic disorders: can or should they be defined?. Am J Med Genet. 2002;108:29\u201335.","journal-title":"Am J Med Genet"},{"key":"1945_CR94","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMra050700","volume":"354","author":"CC Morton","year":"2006","unstructured":"Morton CC, Nance WE. Newborn hearing screening\u2014a silent revolution. N Engl J Med. 2006;354:2151\u201364.","journal-title":"N Engl J Med"},{"key":"1945_CR95","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/hmg\/11.10.1229","volume":"11","author":"CC Morton","year":"2002","unstructured":"Morton CC. Genetics, genomics and gene discovery in the auditory system. Hum Mol Genet. 2002;11:1229\u201340.","journal-title":"Hum Mol Genet"},{"key":"1945_CR96","doi-asserted-by":"crossref","unstructured":"Shakespeare T. Disability rights and wrongs revisited. 2nd ed. London: Routledge; 2014.","DOI":"10.4324\/9781315887456"},{"key":"1945_CR97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/15265161.2021.2013991","volume":"22","author":"E Kleiderman","year":"2022","unstructured":"Kleiderman E, Rahimzadeh V, Knoppers B, Roy MC, Laberge AM, Ravitsky V. The serious factor in expanded prenatal genetic testing. Am J Bioeth. 2022;22:23\u20135.","journal-title":"Am J Bioeth"},{"key":"1945_CR98","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41431-021-01002-9","volume":"30","author":"AJ Newson","year":"2022","unstructured":"Newson AJ, Dive L. Taking seriousness seriously in genomic health. Eur J Hum Genet. 2022;30:140\u20131.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR99","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76:e159\u2013e240.","journal-title":"J Am Coll Cardiol"},{"key":"1945_CR100","doi-asserted-by":"publisher","first-page":"e194428","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2:e194428.","journal-title":"JAMA Netw Open"},{"key":"1945_CR101","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/ejhg.2010.100","volume":"18","author":"G Kosztol\u00e1nyi","year":"2010","unstructured":"Kosztol\u00e1nyi G, Cassiman JJ. The medical geneticist as expert in the transgenerational and developmental aspects of diseases. Eur J Hum Genet. 2010;18:1075\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR102","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jacl.2021.08.007","volume":"15","author":"TP Leren","year":"2021","unstructured":"Leren TP, Bogsrud MP. The importance of cascade genetic screening for diagnosing autosomal dominant hypercholesterolemia: Results from twenty years of a national screening program in Norway. J Clin Lipidol. 2021;15:674\u201381.","journal-title":"J Clin Lipidol"},{"key":"1945_CR103","first-page":"244","volume":"4","author":"MC van Maarle","year":"2001","unstructured":"van Maarle MC, Stouthard ME, Marang-van de Mheen PJ, Klazinga NS, Bonsel GJ. How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees\u2019 views. Community Genet. 2001;4:244\u201352.","journal-title":"Community Genet"},{"key":"1945_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.atherosclerosissup.2017.05.019","volume":"30","author":"L Louter","year":"2017","unstructured":"Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: practical consequences. Atheroscler Suppl. 2017;30:77\u201385.","journal-title":"Atheroscler Suppl"},{"key":"1945_CR105","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MOL.0000000000000832","volume":"33","author":"TP Leren","year":"2022","unstructured":"Leren TP, Bogsrud MP. Cascade screening for familial hypercholesterolemia should be organized at a national level. Curr Opin Lipidol. 2022;33:231\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"1945_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102013","volume":"46","author":"JA Durhuus","year":"2024","unstructured":"Durhuus JA, Galanakis M, Maltesen T, Therkildsen C, Rosth\u00f8j S, Klarskov LL, et al. A registry-based study on universal screening for defective mismatch repair in colorectal cancer in Denmark highlights disparities in screening uptake and counselling referrals. Transl Oncol. 2024;46:102013.","journal-title":"Transl Oncol"},{"key":"1945_CR107","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MOL.0000000000000714","volume":"31","author":"S Ibrahim","year":"2020","unstructured":"Ibrahim S, Reeskamp LF, Stroes ESG, Watts GF. Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. Curr Opin Lipidol. 2020;31:347\u201355.","journal-title":"Curr Opin Lipidol"},{"key":"1945_CR108","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/mrdd.20119","volume":"12","author":"DB Bailey Jr.","year":"2006","unstructured":"Bailey DB Jr., Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev. 2006;12:270\u20139.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"1945_CR109","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nrg2666","volume":"10","author":"Y Bombard","year":"2009","unstructured":"Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM, Cornel MC, et al. The expansion of newborn screening: is reproductive benefit an appropriate pursuit?. Nat Rev Genet. 2009;10:666\u20137.","journal-title":"Nat Rev Genet"},{"key":"1945_CR110","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1089\/gtmb.2010.0232","volume":"15","author":"F Vansenne","year":"2011","unstructured":"Vansenne F, de Borgie CA, Legdeur M, Spauwen MO, Peters M. Providing genetic risk information to parents of newborns with sickle cell trait: role of the general practitioner in neonatal screening. Genet Test Mol Biomark. 2011;15:671\u20135.","journal-title":"Genet Test Mol Biomark"},{"key":"1945_CR111","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3389\/fped.2020.00300","volume":"8","author":"C R\u00e9mus","year":"2020","unstructured":"R\u00e9mus C, Stanislas A, Bouazza N, Gauthereau V, Polak M, Blanche S, et al. An evaluation of three ways of communicating carrier status results to the parents of children in a neonatal sickle cell screening programme. Front Pediatr. 2020;8:300.","journal-title":"Front Pediatr"},{"key":"1945_CR112","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/ejhg.2014.126","volume":"23","author":"F Ulph","year":"2015","unstructured":"Ulph F, Cullinan T, Qureshi N, Kai J. Parents\u2019 responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening. Eur J Hum Genet. 2015;23:459\u201365.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR113","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ejhg.2015.104","volume":"24","author":"M Noke","year":"2016","unstructured":"Noke M, Peters S, Wearden A, Ulph F. A qualitative study to explore how professionals in the United Kingdom make decisions to test children for a sickle cell carrier status. Eur J Hum Genet. 2016;24:164\u201370.","journal-title":"Eur J Hum Genet"},{"key":"1945_CR114","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41431-018-0224-1","volume":"26","author":"P Pujol","year":"2018","unstructured":"Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, et al. Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. Eur J Hum Genet. 2018;26:1732\u201342.","journal-title":"Eur J Hum Genet"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01945-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:03:22Z","timestamp":1769774602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01945-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01945-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}